Truncated ATP7B AAV Constructs for Wilson Disease Copper Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Wilson disease, such as chelating agents and liver transplantation, are not effective for all patients and require immune suppression, highlighting the need for a more sustainable and efficient treatment approach.
Innovation Solution
The use of adeno-associated viral vectors to deliver a truncated yet functional ATP7B protein, specifically lacking metal-binding domains 1-3 but retaining the serine-rich loop, to address copper accumulation in Wilson disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chelating agents are used for treatment, then copper removal is achieved, but treatment effectiveness is limited and not all patients respond
Solution Approach 1:
The patent employs gene therapy to restore the patient's own ATP7B protein function, enabling the body's natural copper excretion mechanisms to function properly. This self-service approach allows the patient's cells to produce functional copper-transporting ATPase, eliminating reliance on external chelating agents and achieving reliable, sustained copper removal without the variability of drug response.
Solution Approach 2:
The patent extracts and corrects the specific genetic defect by delivering a functional copy of the ATP7B gene via AAV vector, replacing the defective gene function. This targeted extraction of the genetic cause allows for precise restoration of copper transport function, improving reliability while adapting to the specific genetic defect in each patient.
2Reliability
If liver transplantation is performed, then copper accumulation is resolved, but immune suppression is required
Solution Approach 1:
The gene therapy approach restores the patient's endogenous copper excretion capability through ATP7B protein expression in hepatocytes, eliminating the need for liver transplantation. This self-service mechanism resolves copper accumulation while avoiding the complexity of immune suppression regimens, as the patient's own liver cells are empowered to function normally.
Solution Approach 2:
The patent extracts the specific functional deficiency (ATP7B protein defect) and replaces it with a functional gene copy, rather than replacing the entire liver organ. This targeted extraction approach resolves the copper accumulation problem while avoiding the need for transplantation and its associated immune suppression requirements.
3Reliability
If wild-type ATP7B is used for gene therapy, then copper transport function is restored, but manufacturing efficiency is reduced
Solution Approach 1:
The patent extracts and removes the problematic metal-binding domains (MBDs 1-3) from the ATP7B protein structure, retaining only the essential copper transport functionality. This truncated version (ATP7B Δ1-3-SS) maintains sufficient copper transport activity while enabling superior manufacturing efficiency and higher expression levels in the AAV gene therapy system.
Solution Approach 2:
The patent modifies the ATP7B protein parameters by deleting specific metal-binding domains and retaining the serine-rich loop, creating a truncated version with optimized properties. This parameter change (from full-length to truncated) improves manufacturing efficiency and expression levels while preserving the essential copper transport function needed for therapeutic effect.
4Ease of manufacture
If truncated ATP7B is used, then manufacturing ease is improved, but protein functionality may be compromised
Solution Approach 1:
The patent optimizes the truncation parameters of ATP7B by deleting MBDs 1-3 while preserving the serine-rich loop and MBD4, achieving the optimal balance between manufacturing efficiency and functional activity. This specific parameter configuration enables high-level expression and easy manufacturing while maintaining sufficient copper transport function for effective WD treatment.
Solution Approach 2:
The patent selectively extracts and removes only the problematic N-terminal metal-binding domains (1-3) that interfere with manufacturing, while preserving the critical C-terminal domains (including the serine-rich loop and MBD4) essential for copper transport function. This selective extraction achieves manufacturing ease without compromising therapeutic functionality.
Data Source
AI summary
This application relates to adeno-associated viral vectors encoding a truncated yet functional ATP7B for use in gene therapy for treating Wilson disease (WD). The truncated ATP7B described herein has several advantages over the wild-type ATP7B such as higher efficacy and improved manufacturing yield.